Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Argiris Symeonidis

Showing results (61-70 of 138) with videos related to

Pageof 14
Sort By:
Blood Advances|December 27, 2024
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER studyVikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, et al.
Leukemia & Lymphoma|November 5, 2021
Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-AzacytidineChristina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Andreas Giannopoulos, et al.
Haematologica|October 26, 2010
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisNicolaus Kröger, Tatjana Zabelina, Anja van Biezen, et al.
American Journal of Hematology|October 15, 2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study groupEirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, et al.
Cancers|June 10, 2022
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, et al.
Medicina (Kaunas, Lithuania)|August 27, 2021
TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in GreeceIoannis Kakkas, Gerasimina Tsinti, Fani Kalala, et al.
International Journal of Hematology|November 6, 2016
A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in GreeceVasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, et al.
British Journal of Haematology|May 16, 2020
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry GroupUrsula Rochau, Igor Stojkov, Annette Conrads-Frank, et al.
Plos One|October 12, 2013
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized dataRonald Brand, Hein Putter, Anja van Biezen, et al.
Leukemia|June 14, 2018
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDSPierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.
Pageof 14

Showing results (61-70 of 138) with videos related to

Sort By:
Pageof 14
Blood Advances|December 27, 2024
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER studyVikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, et al.
Leukemia & Lymphoma|November 5, 2021
Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-AzacytidineChristina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Andreas Giannopoulos, et al.
Haematologica|October 26, 2010
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosisNicolaus Kröger, Tatjana Zabelina, Anja van Biezen, et al.
American Journal of Hematology|October 15, 2013
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study groupEirini Katodritou, Evangelos Terpos, Charikleia Kelaidi, et al.
Cancers|June 10, 2022
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD"Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, et al.
Medicina (Kaunas, Lithuania)|August 27, 2021
TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in GreeceIoannis Kakkas, Gerasimina Tsinti, Fani Kalala, et al.
International Journal of Hematology|November 6, 2016
A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in GreeceVasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, et al.
British Journal of Haematology|May 16, 2020
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry GroupUrsula Rochau, Igor Stojkov, Annette Conrads-Frank, et al.
Plos One|October 12, 2013
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized dataRonald Brand, Hein Putter, Anja van Biezen, et al.
Leukemia|June 14, 2018
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDSPierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.
Pageof 14